Valneva SE (VALN) Curent Deferred Tax Liability (2023 - 2024)
Valneva SE (VALN) posted Curent Deferred Tax Liability of -$14.9 million for Q4 2024, down 6.58% sequentially from -$14.0 million in Q4 2023, and down 6.58% YoY from -$15.9 million in Q1 2024.
Valneva SE (VALN) Curent Deferred Tax Liability (2023 - 2024) Analysis & Trends
Valneva SE has reported Curent Deferred Tax Liability for 2 years, with the latest figure at -$14.9 million in Q4 2024.
- Quarterly Curent Deferred Tax Liability fell 6.58% year-over-year to -$14.9 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$14.9 million (down 6.58% YoY) and the FY2024 annual result came in at -$15.1 million, down 7.37% from the prior year.
- Curent Deferred Tax Liability retreated to -$14.9 million in Q4 2024 per VALN's latest filing, from -$14.0 million in the prior quarter.
- Over five years, Curent Deferred Tax Liability peaked at -$14.0 million in Q4 2023 and troughed at -$14.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Valneva SE | 618.67 Mn | 477.41 Mn | 1.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -14.87 Mn |
| Dec 31, 2024 | -14.87 Mn |
| Dec 31, 2023 | -13.95 Mn |
| Dec 31, 2023 | -13.95 Mn |